Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.

Expert review of pharmacoeconomics & outcomes research - 1 Dec 2014

Seguí Miguel Ángel, Crespo Carlos, Cortés Javier, Lluch Ana, Brosa Max, Becerra Virginia, Chiavenna Sebastián Matias, Gracia Alfredo

Abstract excerpt

BACKGROUND: Cost-effectiveness analysis of MammaPrint(®) (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. METHODS: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant!...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Support Techniques

Share to Drug Costs

Share to Health Care Costs

Share to Models, Economic

Share to National Health Programs

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 25213317
DOI: 10.1586/14737167.2014.957185

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.PMID 25213317Read ↗

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trialSemantic proximity Read ↗

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Genomic Profiling in Early Breast Cancer in ColombiaSemantic proximity Read ↗

Cost-utility analysis of genomic profiling in early breast cancer in ColombiaSemantic proximity Read ↗

Estimated survival outcomes and absolute chemotherapy treatment benefit using PREDICT Tool® and EndoPredict®, in hormone-positive early-stage breast cancer.Semantic proximity Read ↗

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signatureSemantic proximity Read ↗

Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSemantic proximity Read ↗

[Impact of the 21-gene assay in decision-making during multidisciplinary breast meeting: A French experience].Semantic proximity Read ↗

Prediction of the 70-gene signature (MammaPrint) high versus low risk by nomograms among axillary lymph node positive (LN+) and negative (LN-) Chinese breast cancer patients, a retrospective studySemantic proximity Read ↗

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studySemantic proximity Read ↗

Performance Characteristics of the MammaPrint ® Breast Cancer Diagnostic Gene SignatureSemantic proximity Read ↗

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.